• Filing Date: 2020-11-03
  • Form Type: 10-Q
  • Description: Quarterly report
Intangible Asset
9 Months Ended
Sep. 30, 2020
Intangible Asset [Abstract]  
Intangible Asset 8. INTANGIBLE ASSET

As a result of the approval of ILUVIEN by the U.S. Food and Drug Administration (FDA) in 2014, the Company was required to pay EyePoint Pharmaceuticals, Inc. (EyePoint) a milestone payment of $25,000,000 (see Note 9).

The gross carrying amount of the intangible asset is $25,000,000, which is being amortized over approximately 13 years from the acquisition date. The amortization expense related to the intangible asset was approximately $489,000 for both the three months ended September 30, 2020 and 2019, respectively. The amortization expense related to the intangible asset was approximately $1,457,000 for the nine months ended September 30, 2020 and $1,451,000 for the nine months ended September 30, 2019. The net book value of the intangible asset was $13,327,000 and $14,783,000 as of September 30, 2020 and December 31, 2019, respectively.

The estimated future amortization expense as of September 30, 2020 for the remaining periods in the next five years and thereafter is as follows:

Years Ending December 31

(In thousands)

2020 (remaining)
















Property and equipment and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. When indicators of impairment are present, the Company evaluates the carrying amount of such assets in relation to the operating performance and future estimated undiscounted net cash flows expected to be generated by the assets. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. The assessment of the recoverability of assets will be impacted if estimated future operating cash flows are not achieved.

In April of 2020, as a result of the potential impact of the COVID-19 pandemic on the Company’s statements of operations, the Company performed an asset impairment analysis by comparing future undiscounted cash flows of the identified asset group to the carrying value of that asset group. The Company concluded no impairment was necessary.